PD-L1 expression on tumor cells and tumor infiltrating immune cells in Chinese colorectal cancer patients.
Jianjun Yang(Xijing Hospital), Yuezong Bai(Hua Medicine (China)), Guanghui Xu(Xijing Hospital), Xiaochen Zhao, Jiangpeng Wei(Xijing Hospital), Haoyu Wang(Northeast Agricultural University), Wei Zhou(Broad Institute), Anliang Yao(Xijing Hospital), Yuwei Cong, Jiyang Zheng(Northwest University), Fuyan Zhao(Xijing Hospital), Kunli Du(Air Force Medical University)
Cited by 1
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
|Journal of Thoracic Oncology|2016|156
Glutamate 301 of the mouse gonadotropin-releasing hormone receptor confers specificity for arginine 8 of mammalian gonadotropin-releasing hormone.
|Journal of Biological Chemistry|1994|141